Obstructive sleep apnea (OSA) is common and has major health implications but treatment
options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle
activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared
to normal subjects. In this protocol the investigators will test the effect of DAW1033D
administered before sleep on OSA phenotype traits and OSA severity during sleep.